)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Replimune Group
Replimune Group (REPL) investor relations material
Replimune Group 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary14 Jan, 2026
Conference and Strategic Overview
The 44th Annual JPMorgan Healthcare Conference featured a presentation by the CEO, emphasizing the company's turnaround, strategic vision, and readiness to deliver on the promise of oncolytic immunotherapy.
The RPx platform is designed for both local and systemic anti-tumor effects, with deep and superficial injection capabilities.
Technical difficulties delayed the start, but the session focused on forward-looking statements and resilience in 2024.
Clinical Development, Data Highlights, and Trial Progress
Over 1,000 deep injections and more than 1,000 patients treated, demonstrating reproducible and durable systemic responses, especially in hard-to-treat melanoma.
IGNYTE trial in anti-PD-1 failed melanoma showed a 34% response rate in primary resistant patients, with durable responses and FDA confirmation of trial design for registration.
IGNYTE study in anti-PD-1 failed melanoma showed 33.6% ORR and durable responses across resistant subgroups.
Confirmatory IGNYTE-3 study in advanced melanoma is enrolling globally, with interim OS analysis planned for 2H 2027.
ARTACUS study in solid organ transplant patients with CSCC showed 34.6% ORR and durable responses.
Efficacy and Safety Highlights
RP1 plus nivolumab demonstrated improved ORR and time to progression compared to prior anti-PD-1 regimens.
Deep/visceral injections showed enhanced ORR and acceptable safety in difficult-to-treat settings, with safety profile similar to superficial injections and low complication rates.
Neoadjuvant RP1 monotherapy in low-risk, resectable cSCC achieved 100% ORR and was well tolerated.
Monotherapy RP1 shows promise in immunocompromised and transplant patients, with no observed organ rejection.
Expected label breadth for RP1 approval?
IR adoption strategy for deep injections
Top RP1 monotherapy indication beyond melanoma?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Replimune Group earnings date
Q3 202611 Feb, 2026
Replimune Group
Next Replimune Group earnings date
Q3 202611 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Replimune Group Inc. is a biotechnology company focused on the development of oncolytic immunotherapies for the treatment of cancer. The company leverages its proprietary Immulytic platform to engineer viruses that selectively replicate within tumors, stimulating an immune response to attack the cancer cells. Replimune's therapies are designed to be used in combination with other immuno-oncology treatments to enhance their effectiveness. The company targets various forms of cancer, aiming to improve outcomes for patients with difficult-to-treat malignancies. The company is headquartered in Woburn, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage